Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Erin Law, MSc
Advertisement
Miss Law is a consultant at Lifescience Dynamics in London with several years of experience in Biopharma consulting. She has developed expertise in immunology, neurology and women’s health through supporting various clients in competitive intelligence projects.
Articles by Erin Law, MSc
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
2
Rapid Antidepressants and Suicide Risk: What Do We Really Know?
3
The Real-World Burden of Adult ADHD
4
Why Diagnosis Remains Psychiatry's Hardest Task in MDD
5